Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at?

Jane C. Davies, Eric Alton, Ameze Simbo, Ronan Murphy, Ishani Seth, Kate Williams, Mark Somerville, Libby Jolly, Steve Morant, Claire Guest
European Respiratory Journal 2019 54: 1900970; DOI: 10.1183/13993003.00970-2019
Jane C. Davies
1National Heart and Lung Institute, Imperial College, London, UK
2Royal Brompton and Harefield NHS Foundation Trust, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: j.c.davies@imperial.ac.uk
Eric Alton
1National Heart and Lung Institute, Imperial College, London, UK
2Royal Brompton and Harefield NHS Foundation Trust, London
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ameze Simbo
1National Heart and Lung Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ameze Simbo
Ronan Murphy
1National Heart and Lung Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ishani Seth
1National Heart and Lung Institute, Imperial College, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kate Williams
3Medical Detection Dogs, Milton Keynes, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kate Williams
Mark Somerville
3Medical Detection Dogs, Milton Keynes, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Libby Jolly
3Medical Detection Dogs, Milton Keynes, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Morant
3Medical Detection Dogs, Milton Keynes, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steve Morant
Claire Guest
3Medical Detection Dogs, Milton Keynes, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Extract

The major cause of lung damage in cystic fibrosis (CF) is infection with bacterial pathogens, the most prevalent of which is Pseudomonas aeruginosa, chronically infecting ∼60% patients by adolescence/adulthood (www.cysticfibrosis.org.uk/news/registry-report-2017). P. aeruginosa may be successfully eradicated, but frequently recurs and establishes biofilms resistant to antibiotics/host defences [1]. Chronic P. aeruginosa is closely linked with pulmonary exacerbation frequency, faster lung function decline and earlier mortality [2]. The huge antibiotic burden imposed upon patients and the resulting bacterial resistance, allergies and toxicities compound the detrimental impact of the infection itself. Chronic P. aeruginosa should be avoided if at all possible; early detection and rapid treatment may be crucial in achieving this.

Abstract

Detection dogs can be trained to distinguish the major cystic fibrosis pathogen, P. aeruginosa, from a range of organisms. High sensitivity/specificity support the harnessing of this skill to detection in clinical airway samples. http://bit.ly/31GHl0Y

Footnotes

  • Conflict of interest: J.C. Davies reports other from Algipharma AS (advisory board and clinical trial lead), other from Bayer AG (UK lead investigator and advisory board), other from Boehringer Ingelheim Pharma GmbH&Co. KG (advisory board), other from Galapagos NV (advisory board, clinical trial leadership), other from ImevaX GmbH (advisory and trial design assistance), other from Nivalis Therapeutics, Inc. (advisory board), other from ProQR Therapeutics III B.V. (advisory board and advice on trial design), other from Proteostasis Therapeutics, Inc. (advisory and clinical trial leadership), other from Raptor Pharmaceuticals, Inc. (advisory board), other from Vertex Pharmaceuticals (Europe) Limited (advisory board and National Co-ord/Global Co-I), other from Enterprise (advisory board), other from Novartis (advisory board), other from Pulmocide (advisory board), other from Flatley (advisory board), other from Nivalis Therapeutics Inc. (advisory board), grants from CF Trust, other from Teva (educational activities), outside the submitted work.

  • Conflict of interest: E. Alton has nothing to disclose.

  • Conflict of interest: A. Simbo has nothing to disclose.

  • Conflict of interest: R. Murphy has nothing to disclose.

  • Conflict of interest: I. Seth has nothing to disclose.

  • Conflict of interest: K. Williams has nothing to disclose.

  • Conflict of interest: M. Somerville has nothing to disclose.

  • Conflict of interest: L. Jolly has nothing to disclose.

  • Conflict of interest: S. Morant has nothing to disclose.

  • Conflict of interest: C. Guest has nothing to disclose.

  • Received May 14, 2019.
  • Accepted July 2, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence
View Full Text
PreviousNext
Back to top
View this article with LENS
Vol 54 Issue 5 Table of Contents
European Respiratory Journal: 54 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at?
Jane C. Davies, Eric Alton, Ameze Simbo, Ronan Murphy, Ishani Seth, Kate Williams, Mark Somerville, Libby Jolly, Steve Morant, Claire Guest
European Respiratory Journal Nov 2019, 54 (5) 1900970; DOI: 10.1183/13993003.00970-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at?
Jane C. Davies, Eric Alton, Ameze Simbo, Ronan Murphy, Ishani Seth, Kate Williams, Mark Somerville, Libby Jolly, Steve Morant, Claire Guest
European Respiratory Journal Nov 2019, 54 (5) 1900970; DOI: 10.1183/13993003.00970-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Erythrocytes are altered in PAH
  • Long COVID symptoms, from an imaginary condition to a recognised syndrome
  • Dupilumab in patients with asthma and blood eosinophils ≥500 cells·µL−1
Show more Agora

Research letters

  • Erythrocytes are altered in PAH
  • Dupilumab in patients with asthma and blood eosinophils ≥500 cells·µL−1
  • NTM-PD incidence among elderly patients with bronchiectasis
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society